IGT 302
Alternative Names: IGT-302Latest Information Update: 03 Nov 2023
At a glance
- Originator INGENIA Therapeutics
- Class Antibodies; Antiglaucomas
- Mechanism of Action TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glaucoma
Most Recent Events
- 20 Oct 2023 IGT 302 is available for licensing as of 20 Oct 2023. https://www.ingeniatx.com/en/sub/technology/pipeline.php
- 19 Oct 2023 Preclinical trials in Glaucoma in USA (Parenteral) prior to October 2023 (INGENIA Therapeutics pipeline, October 2023)